Life Sciences, MRSA, Antibiotics

Rib-X Reveals “Positive” Antibiotic Data

Ryan McBride 12/8/08

Rib-X Pharmaceuticals, a New Haven, CT-based developer of antibiotics, announced that its antibiotic delafloxacin in both 300 mg and 450 mg doses was as effective as an FDA-approved antibiotic in treating patients with complicated skin and skin structure infections in a mid-stage clinical trial. In October I wrote a feature profile about Rib-X and its next-generation antibiotics for treating antibiotic-resistant infections caused by MRSA and other lethal bacteria.

Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.